Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.

doi:10.1002/cncr.32572

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.

Cancer - 1 Feb 2020

Vysotskaia Valentina, Kaseniit K Eerik, Bucheit Leslie, Ready Kaylene, Price Kristin, Johansen Taber Katherine

Abstract excerpt

BACKGROUND: Although management guidelines exist for several genes associated with a 2-fold to 5-fold increase in the relative risk for certain cancers, the value of testing for them remains controversial. METHODS: De-identified personal and family history data for 654 individuals with pathogenic variants (PVs) in PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and/or RAD51D were analyzed for pretest and post-test...

Topics

Adolescent
Adult
Aged
Aged, 80 and over
Ataxia Telangiectasia Mutated Proteins
Breast Neoplasms
Cell Cycle Proteins
Checkpoint Kinase 2
DNA-Binding Proteins
Fanconi Anemia Complementation Group N Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Fanconi Anemia Complementation Group Proteins

Female

Genetic Predisposition to Disease

Genetic Testing

Health Personnel

Hereditary Breast and Ovarian Cancer Syndrome

Humans

Magnetic Resonance Imaging

Source

Open in PubMed Open full text

Identifiers

PMID: 31682005
DOI: 10.1002/cncr.32572
PMCID: PMC7003834

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.PMID 31682005Read ↗

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working GroupSemantic proximity Read ↗

Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer PatientsSemantic proximity Read ↗

Screening Practices for Breast and Nonbreast Cancers in High-Risk Mutation Carriers.Semantic proximity Read ↗

Breast cancer multigene germline panel testing in mainstream oncology based on clinical-public health utility (cancer mortality benefit): ESMO Precision Oncology Working Group recommendationsSemantic proximity Read ↗

Hereditary cancer testing in a diverse sample across three breast imaging centers.Semantic proximity Read ↗

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.Semantic proximity Read ↗

Management of individuals with heterozygous germline pathogenic variants in RAD51C, RAD51D, and BRIP1: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

Leveraging tumor multigene panel testing to identify germline variants in gynecologic cancers: A retrospective evaluation of an algorithm-based approach.Semantic proximity Read ↗

Genetic testing women with newly diagnosed breast cancer: What criteria are the most predictive of a positive test?Semantic proximity Read ↗

Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.Semantic proximity Read ↗

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.Semantic proximity Read ↗

Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.